Inventor · disambiguated record
Luke Evnin
Also filed as: EVNIN LUKE · EVNIN LUKE B
26 granted patents·13 pending applications·266 citations·filing 2003–2025
96Inventor score
Files withHARPOON THERAPEUTICS INC13WEREWOLF THERAPEUTICS INC11AMPHIVENA THERAPEUTICS INC5ONCORUS INC3VIROGIN BIOTECH CANADA LTD2
Top patents by PatentIndex Score
39 records- 0198US9708412B2Trispecific binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2016·Granted Jul 18, 2017·66 cites·12 claims
- 0296US11352403B2Activatable interleukin-2 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2020·Granted Jun 7, 2022·6 cites·13 claims
- 0396US10696724B2Activatable interleukin-2 polypeptidesWEREWOLF THERAPEUTICS INC·Filed 2019·Granted Jun 30, 2020·18 cites·11 claims
- 0496US10100106B2Single domain serum albumin binding proteinHARPOON THERAPEUTICS INC·Filed 2017·Granted Oct 16, 2018·27 cites·26 claims
- 0596US9920115B2Single domain serum albumin binding proteinHARPOON THERAPEUTICS INC·Filed 2017·Granted Mar 20, 2018·31 cites·12 claims
- 0695US10696723B2Activatable interleukin 12 polypeptidesWEREWOLF THERAPEUTICS INC·Filed 2019·Granted Jun 30, 2020·15 cites·12 claims
- 0795US10066016B2Single chain variable fragment CD3 binding proteinsHARPOON THERAPEUTICS INC·Filed 2017·Granted Sep 4, 2018·34 cites·13 claims
- 0894US11535658B2Activatable interleukin-2 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2021·Granted Dec 27, 2022·2 cites·21 claims
- 0993US11981716B2Activatable interleukin-2 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2021·Granted May 14, 2024·2 cites·13 claims
- 1092US12128102B2Constrained conditionally activated binding proteinsTAKEDA PHARMACEUTICALS CO·Filed 2023·Granted Oct 29, 2024·1 cites·15 claims
- 1192US10954311B2Trispecific binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2017·Granted Mar 23, 2021·9 cites·21 claims
- 1292US10544221B2Single chain variable fragment CD3 binding proteinsHARPOON THERAPEUTICS INC·Filed 2017·Granted Jan 28, 2020·14 cites·17 claims
- 1392US9212225B1Bispecific CD33 and CD3 binding proteinsAMPHIVENA THERAPEUTICS INC·Filed 2015·Granted Dec 15, 2015·17 cites·14 claims
- 1490US10604574B2Oncolytic viral delivery of therapeutic polypeptidesONCORUS INC·Filed 2018·Granted Mar 31, 2020·4 cites·6 claims
- 1590US9803029B2Bispecific CD33 and CD3 binding proteinsAMPHIVENA THERAPEUTICS INC·Filed 2015·Granted Oct 31, 2017·11 cites·18 claims
- 1688US10626190B2Bispecific CD33 and CD3 binding proteinsAMPHIVENA THERAPEUTICS INC·Filed 2017·Granted Apr 21, 2020·3 cites·12 claims
- 1785US2025197526A1Trispecific binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1884US10738118B2Methods of using bispecific CD33 and CD3 binding proteinsAMPHIVENA THERAPEUTICS INC·Filed 2016·Granted Aug 11, 2020·3 cites·21 claims
- 1982US11078280B2Oncolytic viral delivery of therapeutic polypeptidesONCORUS INC·Filed 2020·Granted Aug 3, 2021·1 cites·13 claims
- 2081US11623958B2Single chain variable fragment CD3 binding proteinsHARPOON THERAPEUTICS INC·Filed 2020·Granted Apr 11, 2023·1 cites·24 claims
- 2180US11453716B2Single domain serum albumin binding proteinHARPOON THERAPEUTICS INC·Filed 2018·Granted Sep 27, 2022·1 cites·20 claims
- 2278US12275769B2Activatable interleukin 12 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2022·Granted Apr 15, 2025·0 cites·14 claims
- 2376US2024207334A1Oncolytic viral delivery of therapeutic polypeptidesVIROGIN BIOTECH CANADA LTD·Filed 2023·Application pending·0 cites
- 2475US12084518B2Trispecific binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2021·Granted Sep 10, 2024·0 cites·21 claims
- 2575US11739132B2Separation moieties and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2022·Granted Aug 29, 2023·0 cites·16 claims
- 2674US2025179138A1Activatable interleukin 12 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2774US2023272028A1Separation moieties and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2871US2024084009A1Single chain variable fragment cd3 binding proteinsHARPOON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2970US11453710B2Activatable interleukin 12 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2020·Granted Sep 27, 2022·0 cites·16 claims
- 3067US11865081B2Oncolytic viral delivery of therapeutic polypeptidesVIROGIN BIOTECH CANADA LTD·Filed 2018·Granted Jan 9, 2024·0 cites·14 claims
- 3165US2021024654A1Bispecific CD33 and CD3 Binding ProteinsAMPHIVENA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3262US2021115102A1Separation moieties and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3360US11753469B2Methods of using bispecific CD33 and CD3 binding proteinsANJI BRUNO LLC·Filed 2020·Granted Sep 12, 2023·0 cites·22 claims
- 3453US2018057594A1Pseudotyped oncolytic viral delivery of therapeutic polypeptidesONCORUS INC·Filed 2017·Application pending·0 cites
- 3551US2006229685A1Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)KNUDSON MARK B·Filed 2006·Application pending·0 cites
- 3643US2004172084A1Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)Filed 2003·Application pending·0 cites
- 3743US2019225702A1Innate immune cell trispecific binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3843US2020115461A1Compositions and methods for adoptive cell therapiesHARPOON THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3941US2018134789A1Inducible binding proteins and methods of useMAVERICK THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Luke Evnin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →